Regucalcin promotes dormancy of prostate cancer

Sharma, Sambad; Pei, Xinhong; Xing, Fei; Wu, Soon‐Yi; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Deshpande, Ravindra Pramod; Ruiz, Marco Gabriel; Singh, Ravi; Lyu, Feng; Watabe, Kounosuke

doi:10.1038/s41388-020-01565-9

Cited by 22 publications

(27 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When comparing the remaining potential miRNAs, according to the present bioinformatics analysis (miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, and miR-592), all were suggested with important roles in PC screening [61], aggressiveness [8,62,63], and recurrence [7,18,64], or even new etiological values [65] were suggested. These miRNAs have also been highlighted with carcinogenic effects in other tumors, such as endometrial [66,67], osteosarcoma [68], hepatocellular [69], renal [17,70], or colorectal [71], among others [72][73][74].…”

Section: Discussionmentioning

confidence: 81%

“…By contrast, there is just one publication that indicated the role of miR-23c in PC, suggesting its role in dormancy [8]. Other reports suggest this miRNA has a role as a therapeutic target in ovarian cancer [68] and implicate the molecular regulation of endometrial or hepatocellular cancers [66,69].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, miR-23c has been recently indicated as a biomarker for predicting recurrence in PC, by its critical role on RGN (Regucalcin) gene. RGN promotes dormancy in PC [8]. Moreover, miR-23c has been described as an inhibitor of cell proliferation and a promoter of apoptosis by attenuating ERBB2IP (erbb2 interacting protein) [9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such as miR-miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs’ analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D’Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this regard, a recent study demonstrated that miR-23c acts as tumor suppressor in hepatocarcinoma cell lines, by inhibiting cell proliferation and inducing apoptosis through the regulation of the ERBB2IP gene [ 26 ]. In addition, miR-23c secreted from prostate cancer cells expressing regucalcin, a gene involved in tumor dormancy, was found to suppress the angiogenesis in human umbilical vein endothelial cells [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells

Gallo

Carotenuto

Frezzetti

et al. 2022

Cancers

View full text Add to dashboard Cite

We previously demonstrated that the epidermal growth factor receptor (EGFR) modulates in mesenchymal stem cells (MSCs) the expression of a number of genes coding for secreted proteins that promote breast cancer progression. However, the role of the EGFR in modulating in MSCs the expression of miRNAs potentially involved in the progression of breast cancer remains largely unexplored. Following small RNA-sequencing, we identified 36 miRNAs differentially expressed between MSCs untreated or treated with the EGFR ligand transforming growth factor α (TGFα), with a fold change (FC) < 0.56 or FC ≥ 1.90 (CI, 95%). KEGG analysis revealed a significant enrichment in signaling pathways involved in cancer development and progression. EGFR activation in MSCs downregulated the expression of different miRNAs, including miR-23c. EGFR signaling also reduced the secretion of miR-23c in conditioned medium from MSCs. Functional assays demonstrated that miR-23c acts as tumor suppressor in basal/claudin-low MDA-MB-231 and MDA-MB-468 cells, through the repression of IL-6R. MiR-23c downregulation promoted cell proliferation, migration and invasion of these breast cancer cell lines. Collectively, our data suggested that the EGFR signaling regulates in MSCs the expression of miRNAs that might be involved in breast cancer progression, providing novel information on the mechanisms that regulate the MSC-tumor cell cross-talk.

show abstract

“…These cascades drive cell cycle progression through upregulating c-Myc, and drive cell exit from quiescence through increasing cyclins and decreasing CDKIs [48,54]. For example, DIRAS3 and Regulcalcin induce tumour dormancy partially by blocking RAS/MAPK signalling [56,57]. Activated FAK additionally supports cell cycle progression by repressing the transcriptional activity of p53, a transcriptional repressor of c-Myc [54,58].…”

Section: C-myc and Related Signalling Pathwaysmentioning

confidence: 99%

Advances in therapeutic agents targeting quiescent cancer cells

Nabil

Liu

et al. 2022

Acta Materia Medica

View full text Add to dashboard Cite

Quiescent cancer cells (QCCs) reversibly reside in G0 phase, thus allowing them to survive chemotherapy and radiotherapy, which generally target proliferating cells. Surviving QCCs may re-proliferate, and consequently result in cancer progression, recurrence, and metastasis. Therefore, understanding the key players governing QCC survival and activation is crucial for developing QCC-targeting agents. This review presents an overview of (1) the mechanisms underlying the regulation of QCC status and (2) recent advances in the development of QCC-targeting therapeutic agents and their underlying mechanisms. The development of effective therapeutic modalities that target QCCs may enable new cancer treatments to prevent cancer progression and recurrence.

show abstract

Regucalcin promotes dormancy of prostate cancer

Cited by 22 publications

References 60 publications

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells

Advances in therapeutic agents targeting quiescent cancer cells

Contact Info

Product

Resources

About